4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of$ 0.68. This compares to loss of $0.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.24%. A quarter ago, it was expected that this company would post a loss of$ 0.67 per share when it actually produced a loss of $0.24, delivering a surprise of 64.18%.Over the last four quarters, the com ...